| Year |
Citation |
Score |
| 2022 |
Michael E, Covic L, Kuliopulos A. Lipopeptide Pepducins as Therapeutic Agents. Methods in Molecular Biology (Clifton, N.J.). 2383: 307-333. PMID 34766299 DOI: 10.1007/978-1-0716-1752-6_21 |
0.311 |
|
| 2021 |
Lee JL, Ekambaram P, Carleton NM, Hu D, Klei LR, Cai Z, Myers MI, Hubel NE, Covic L, Agnihotri S, Krappmann D, Bornancin F, Lee AV, Oesterreich S, McAllister-Lucas L, et al. MALT1 is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-low, Triple-Negative Breast Cancer. Molecular Cancer Research : McR. PMID 34753803 DOI: 10.1158/1541-7786.MCR-21-0208 |
0.347 |
|
| 2020 |
Van Doren L, Nguyen N, Garzia C, Fletcher E, Stevenson R, Jaramillo D, Kuliopulos A, Covic L. Lipid Receptor GPR31 (G-Protein-Coupled Receptor 31) Regulates Platelet Reactivity and Thrombosis Without Affecting Hemostasis. Arteriosclerosis, Thrombosis, and Vascular Biology. ATVBAHA120315154. PMID 33267659 DOI: 10.1161/ATVBAHA.120.315154 |
0.388 |
|
| 2019 |
McAuley JR, Bailey KM, Ekambaram P, Klei LR, Kang H, Hu D, Freeman TJ, Concel VJ, Hubel NE, Lee JL, Klei HB, Cheng J, Sekar P, Bridwell RE, Covic L, et al. MALT1 is a critical mediator of PAR1-driven NF-κB activation and metastasis in multiple tumor types. Oncogene. PMID 31420608 DOI: 10.1038/S41388-019-0958-4 |
0.427 |
|
| 2019 |
Kimmelstiel C, Stevenson R, Nguyen N, Van Doren L, Zhang P, Perkins J, Kapur NK, Weintraub A, Castaneda V, Kuliopulos A, Covic L. Enhanced potency of prasugrel on protease-activated receptors following bivalirudin treatment for PCI as compared to clopidogrel. Thrombosis Research. 177: 59-69. PMID 30851630 DOI: 10.1016/J.Thromres.2019.01.017 |
0.438 |
|
| 2019 |
Michael ES, Covic L, Kuliopulos A. Trace amine-associated receptor 1 (TAAR1) promotes anti-diabetic signaling in insulin-secreting cells. Journal of Biological Chemistry. 294: 4401-4411. PMID 30670596 DOI: 10.1074/Jbc.Ra118.005464 |
0.353 |
|
| 2019 |
Van Doren L, Nguyen N, Garzia C, Fletcher E, Stevenson R, Jaramillo D, Kuliopulos A, Covic L. Blockade of Lipid Receptor GPR31 Suppresses Platelet Reactivity and Thrombosis with Minimal Effect on Hemostasis Blood. 134: 1064-1064. DOI: 10.1182/Blood-2019-126111 |
0.423 |
|
| 2018 |
Covic L, Kuliopulos A. Protease-Activated Receptor 1 as Therapeutic Target in Breast, Lung, and Ovarian Cancer: Pepducin Approach. International Journal of Molecular Sciences. 19: 2237. PMID 30065181 DOI: 10.3390/Ijms19082237 |
0.453 |
|
| 2018 |
Rana R, Huang T, Koukos G, Fletcher EK, Turner SE, Shearer A, Gurbel PA, Rade JJ, Kimmelstiel CD, Bliden KP, Covic L, Kuliopulos A. Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology. PMID 29622563 DOI: 10.1161/Atvbaha.118.310967 |
0.456 |
|
| 2015 |
Gurbel PA, Bliden KP, Turner SE, Tantry US, Gesheff MG, Barr TP, Covic L, Kuliopulos A. Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology. PMID 26681756 DOI: 10.1161/Atvbaha.115.306777 |
0.358 |
|
| 2015 |
Zhang P, Covic L, Kuliopulos A. Pepducins and Other Lipidated Peptides as Mechanistic Probes and Therapeutics. Methods in Molecular Biology (Clifton, N.J.). 1324: 191-203. PMID 26202271 DOI: 10.1007/978-1-4939-2806-4_13 |
0.404 |
|
| 2015 |
Yang E, Cisowski J, Nguyen N, O'Callaghan K, Xu J, Agarwal A, Kuliopulos A, Covic L. Dysregulated protease activated receptor 1 (PAR1) promotes metastatic phenotype in breast cancer through HMGA2. Oncogene. PMID 26165842 DOI: 10.1038/Onc.2015.217 |
0.437 |
|
| 2015 |
Zhang P, Leger AJ, Baleja JD, Rana R, Corlin T, Nguyen N, Koukos G, Bohm A, Covic L, Kuliopulos A. Allosteric Activation of a G Protein-coupled Receptor with Cell-penetrating Receptor Mimetics. The Journal of Biological Chemistry. 290: 15785-98. PMID 25934391 DOI: 10.1074/Jbc.M115.636316 |
0.46 |
|
| 2014 |
Foley CJ, Fanjul-Fernández M, Bohm A, Nguyen N, Agarwal A, Austin K, Koukos G, Covic L, López-Otín C, Kuliopulos A. Matrix metalloprotease 1a deficiency suppresses tumor growth and angiogenesis Oncogene. 33: 2264-2272. PMID 23708660 DOI: 10.1038/Onc.2013.157 |
0.389 |
|
| 2014 |
Zhang P, Covic L, Kuliopulos A. Platelet Receptors and Drug Targets: PAR1, Collagen, vWF, Thromboxane, and Other Novel Targets Antiplatelet Therapy in Cardiovascular Disease. 29-44. DOI: 10.1002/9781118493984.ch5 |
0.371 |
|
| 2013 |
Austin KM, Nguyen N, Javid G, Covic L, Kuliopulos A. Noncanonical matrix metalloprotease-1-protease-activated receptor-1 signaling triggers vascular smooth muscle cell dedifferentiation and arterial stenosis. The Journal of Biological Chemistry. 288: 23105-15. PMID 23814055 DOI: 10.1074/Jbc.M113.467019 |
0.408 |
|
| 2013 |
Kaimal R, Aljumaily R, Tressel SL, Pradhan RV, Covic L, Kuliopulos A, Zarwan C, Kim YB, Sharifi S, Agarwal A. Selective blockade of matrix metalloprotease-14 with a monoclonal antibody abrogates invasion, angiogenesis, and tumor growth in ovarian cancer. Cancer Research. 73: 2457-67. PMID 23423981 DOI: 10.1158/0008-5472.Can-12-1426 |
0.343 |
|
| 2013 |
Austin KM, Covic L, Kuliopulos A. Matrix metalloproteases and PAR1 activation. Blood. 121: 431-9. PMID 23086754 DOI: 10.1182/Blood-2012-09-355958 |
0.43 |
|
| 2013 |
Zhang P, Covic L, Kuliopulos A. Protease-Activated Receptors Platelets. 249-259. DOI: 10.1016/B978-0-12-387837-3.00013-4 |
0.335 |
|
| 2012 |
Zhang P, Gruber A, Kasuda S, Kimmelstiel C, O'Callaghan K, Cox DH, Bohm A, Baleja JD, Covic L, Kuliopulos A. Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin. Circulation. 126: 83-91. PMID 22705889 DOI: 10.1161/Circulationaha.112.091918 |
0.301 |
|
| 2012 |
Foley CJ, Luo C, O'Callaghan K, Hinds PW, Covic L, Kuliopulos A. Matrix metalloprotease-1a promotes tumorigenesis and metastasis Journal of Biological Chemistry. 287: 24330-24338. PMID 22573325 DOI: 10.1074/Jbc.M112.356303 |
0.413 |
|
| 2012 |
O'Callaghan K, Kuliopulos A, Covic L. Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development. The Journal of Biological Chemistry. 287: 12787-96. PMID 22374997 DOI: 10.1074/Jbc.R112.355461 |
0.454 |
|
| 2012 |
O'Callaghan K, Lee L, Nguyen N, Hsieh MY, Kaneider NC, Klein AK, Sprague K, Van Etten RA, Kuliopulos A, Covic L. Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia. Blood. 119: 1717-25. PMID 22186993 DOI: 10.1182/Blood-2011-04-347518 |
0.376 |
|
| 2011 |
Sevigny LM, Austin KM, Zhang P, Kasuda S, Koukos G, Sharifi S, Covic L, Kuliopulos A. Protease-activated receptor-2 modulates protease-activated receptor-1-driven neointimal hyperplasia. Arteriosclerosis, Thrombosis, and Vascular Biology. 31: e100-6. PMID 21940952 DOI: 10.1161/Atvbaha.111.238261 |
0.406 |
|
| 2011 |
Cisowski J, O'Callaghan K, Kuliopulos A, Yang J, Nguyen N, Deng Q, Yang E, Fogel M, Tressel S, Foley C, Agarwal A, Hunt SW, McMurry T, Brinckerhoff L, Covic L. Targeting protease-activated receptor-1 with cell-penetrating pepducins in lung cancer. The American Journal of Pathology. 179: 513-23. PMID 21703428 DOI: 10.1016/J.Ajpath.2011.03.025 |
0.404 |
|
| 2011 |
Dimond P, Carlson K, Bouvier M, Gerard C, Xu L, Covic L, Agarwal A, Ernst OP, Janz JM, Schwartz TW, Gardella TJ, Milligan G, Kuliopulos A, Sakmar TP, Hunt SW. G protein-coupled receptor modulation with pepducins: moving closer to the clinic. Annals of the New York Academy of Sciences. 1226: 34-49. PMID 21615752 DOI: 10.1111/J.1749-6632.2011.06039.X |
0.418 |
|
| 2011 |
Tressel SL, Kaneider NC, Kasuda S, Foley C, Koukos G, Austin K, Agarwal A, Covic L, Opal SM, Kuliopulos A. A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. Embo Molecular Medicine. 3: 370-84. PMID 21591259 DOI: 10.1002/Emmm.201100145 |
0.351 |
|
| 2011 |
Koukos G, Sevigny L, Zhang P, Covic L, Kuliopulos A. Serine and metalloprotease signaling through PAR1 in arterial thrombosis and vascular injury. Iubmb Life. 63: 412-8. PMID 21557445 DOI: 10.1002/Iub.465 |
0.464 |
|
| 2011 |
Sevigny LM, Zhang P, Bohm A, Lazarides K, Perides G, Covic L, Kuliopulos A. Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducins. Proceedings of the National Academy of Sciences of the United States of America. 108: 8491-6. PMID 21536878 DOI: 10.1073/Pnas.1017091108 |
0.491 |
|
| 2011 |
Kimmelstiel C, Zhang P, Kapur NK, Weintraub A, Krishnamurthy B, Castaneda V, Covic L, Kuliopulos A. Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention. Circulation. Cardiovascular Interventions. 4: 171-9. PMID 21364148 DOI: 10.1161/Circinterventions.110.959098 |
0.38 |
|
| 2011 |
Tressel SL, Koukos G, Tchernychev B, Jacques SL, Covic L, Kuliopulos A. Pharmacology, biodistribution, and efficacy of GPCR-based pepducins in disease models. Methods in Molecular Biology (Clifton, N.J.). 683: 259-75. PMID 21053136 DOI: 10.1007/978-1-60761-919-2_19 |
0.474 |
|
| 2011 |
Covic L, O’Callaghan KM, Ngyen N, Mo-Ying H, Klein AK, Sprague K, Etten RAV, Kuliopulos A. Targeting CXCR4 with Cell-Penetrating Pepducins Enhances Survival in Disseminated Lymphoma Blood. 118: 4244-4244. DOI: 10.1182/Blood.V118.21.4244.4244 |
0.382 |
|
| 2010 |
Agarwal A, Tressel SL, Kaimal R, Balla M, Lam FH, Covic L, Kuliopulos A. Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: implications for antiangiogenic therapy. Cancer Research. 70: 5880-90. PMID 20570895 DOI: 10.1158/0008-5472.Can-09-4341 |
0.447 |
|
| 2010 |
Swift S, Xu J, Trivedi V, Austin KM, Tressel SL, Zhang L, Covic L, Kuliopulos A. A novel protease-activated receptor-1 interactor, Bicaudal D1, regulates G protein signaling and internalization. The Journal of Biological Chemistry. 285: 11402-10. PMID 20164183 DOI: 10.1074/Jbc.M110.105403 |
0.423 |
|
| 2009 |
Yang E, Boire A, Agarwal A, Nguyen N, O'Callaghan K, Tu P, Kuliopulos A, Covic L. Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. Cancer Research. 69: 6223-31. PMID 19622769 DOI: 10.1158/0008-5472.Can-09-0187 |
0.405 |
|
| 2009 |
Trivedi V, Boire A, Tchernychev B, Kaneider NC, Leger AJ, O'Callaghan K, Covic L, Kuliopulos A. Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell. 137: 332-43. PMID 19379698 DOI: 10.1016/J.Cell.2009.02.018 |
0.431 |
|
| 2009 |
O'Callaghan KM, Hsieh M, VanEtten RA, Covic L, Kuliopulos A. CXCR4 Pepducins in Stem Cell Mobilization. Blood. 114: 2440-2440. DOI: 10.1182/Blood.V114.22.2440.2440 |
0.342 |
|
| 2009 |
Agarwal A, Tressel S, Kaimal R, Bala M, Iam F, Covic L, Kuliopulos A. Abstract B13: Identification of a metalloprotease‐chemokine signaling system in the ovarian cancer microenvironment: Implications for antiangiogenic therapy Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B13 |
0.417 |
|
| 2008 |
Agarwal A, Covic L, Sevigny LM, Kaneider NC, Lazarides K, Azabdaftari G, Sharifi S, Kuliopulos A. Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer. Molecular Cancer Therapeutics. 7: 2746-57. PMID 18790755 DOI: 10.1158/1535-7163.Mct-08-0177 |
0.418 |
|
| 2008 |
Hatziapostolou M, Polytarchou C, Panutsopulos D, Covic L, Tsichlis PN. Proteinase-activated receptor-1-triggered activation of tumor progression locus-2 promotes actin cytoskeleton reorganization and cell migration. Cancer Research. 68: 1851-61. PMID 18339866 DOI: 10.1158/0008-5472.Can-07-5793 |
0.434 |
|
| 2007 |
Kaneider NC, Leger AJ, Agarwal A, Nguyen N, Perides G, Derian C, Covic L, Kuliopulos A. 'Role reversal' for the receptor PAR1 in sepsis-induced vascular damage. Nature Immunology. 8: 1303-12. PMID 17965715 DOI: 10.1038/Ni1525 |
0.324 |
|
| 2007 |
Yang EJ, Agarwal A, Nguyen N, Kuliopulos A, Covic L. 97 Synergistic Enhancement Of Breast Cancer Chemotherapy By Par1 Pepducins. Journal of Investigative Medicine. 55. DOI: 10.1136/Jim-55-02-97 |
0.414 |
|
| 2006 |
Leger AJ, Covic L, Kuliopulos A. Protease-activated receptors in cardiovascular diseases. Circulation. 114: 1070-7. PMID 16952995 DOI: 10.1161/Circulationaha.105.574830 |
0.502 |
|
| 2006 |
Nguyen N, Kuliopulos A, Graham RA, Covic L. Tumor-derived Cyr61(CCN1) promotes stromal matrix metalloproteinase-1 production and protease-activated receptor 1-dependent migration of breast cancer cells. Cancer Research. 66: 2658-65. PMID 16510585 DOI: 10.1158/0008-5472.Can-05-2082 |
0.408 |
|
| 2006 |
Leger AJ, Jacques SL, Badar J, Kaneider NC, Derian CK, Andrade-Gordon P, Covic L, Kuliopulos A. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation. 113: 1244-54. PMID 16505172 DOI: 10.1161/Circulationaha.105.587758 |
0.461 |
|
| 2006 |
Leger AJ, Covic L, Kuliopulos A. Identification and Targeting of a PAR1-PAR4 Complex in Human Platelets and Thrombosis. Blood. 108: 1511-1511. DOI: 10.1182/Blood.V108.11.1511.1511 |
0.414 |
|
| 2005 |
Kimmelstiel C, Badar J, Covic L, Waxman S, Weintraub A, Jacques S, Kuliopulos A. Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage. Thrombosis Research. 116: 55-66. PMID 15850609 DOI: 10.1016/J.Thromres.2004.11.011 |
0.363 |
|
| 2005 |
Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell. 120: 303-13. PMID 15707890 DOI: 10.1016/J.Cell.2004.12.018 |
0.471 |
|
| 2004 |
Kuliopulos A, Mohanlal R, Covic L. Effect of selective inhibition of the p38 MAP kinase pathway on platelet aggregation. Thrombosis and Haemostasis. 92: 1387-93. PMID 15583748 DOI: 10.1160/Th04-03-0187 |
0.397 |
|
| 2003 |
Seeley S, Covic L, Jacques SL, Sudmeier J, Baleja JD, Kuliopulos A. Structural basis for thrombin activation of a protease-activated receptor: inhibition of intramolecular liganding. Chemistry & Biology. 10: 1033-41. PMID 14652070 DOI: 10.1016/J.Chembiol.2003.10.014 |
0.414 |
|
| 2003 |
Stampfuss JJ, Schrör K, Weber AA, Covic L, Jacques S, Kuliopulos A. Inhibition of platelet thromboxane receptor function by a thrombin receptor-targeted pepducin [1] (multiple letters) Nature Medicine. 9: 1447-1448. PMID 14647510 |
0.347 |
|
| 2003 |
Kuliopulos A, Covic L. Blocking receptors on the inside: pepducin-based intervention of PAR signaling and thrombosis. Life Sciences. 74: 255-62. PMID 14607253 DOI: 10.1016/J.Lfs.2003.09.012 |
0.509 |
|
| 2003 |
Covic L, Jacques S, Kuliopulos A. Reply to “Inhibition of platelet thromboxane receptor function by a thrombin receptor–targeted pepducin” Nature Medicine. 9: 1447-1448. DOI: 10.1038/Nm1203-1447B |
0.402 |
|
| 2002 |
Covic L, Misra M, Badar J, Singh C, Kuliopulos A. Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nature Medicine. 8: 1161-5. PMID 12357249 DOI: 10.1038/Nm760 |
0.495 |
|
| 2002 |
Covic L, Singh C, Smith H, Kuliopulos A. Role of the PAR4 thrombin receptor in stabilizing platelet-platelet aggregates as revealed by a patient with Hermansky-Pudlak syndrome. Thrombosis and Haemostasis. 87: 722-7. PMID 12008957 DOI: 10.1055/S-0037-1613071 |
0.392 |
|
| 2002 |
Covic L, Gresser AL, Talavera J, Swift S, Kuliopulos A. Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. Proceedings of the National Academy of Sciences of the United States of America. 99: 643-8. PMID 11805322 DOI: 10.1073/Pnas.022460899 |
0.451 |
|
| 2000 |
Covic L, Gresser AL, Kuliopulos A. Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets. Biochemistry. 39: 5458-67. PMID 10820018 DOI: 10.1021/Bi9927078 |
0.426 |
|
| 2000 |
Swift S, Sheridan PJ, Covic L, Kuliopulos A. PAR1 thrombin receptor-G protein interactions: Separation of binding and coupling determinants in the Gα subunit Journal of Biological Chemistry. 275: 2627-2635. PMID 10644723 DOI: 10.1074/Jbc.275.4.2627 |
0.348 |
|
| 2000 |
Covic L, Gresser AL, Kuliopulos A. Extracellular liganding of the pari thrombin receptor by a novel class of cell penetrating peptides Blood. 96: 244a. |
0.395 |
|
| 1999 |
Kuliopulos A, Covic L, Seeley SK, Sheridan PJ, Helin J, Costello CE. Plasmin desensitization of the PAR1 thrombin receptor: Kinetics, sites of truncation, and implications for thrombolytic therapy Biochemistry. 38: 4572-4585. PMID 10194379 DOI: 10.1021/Bi9824792 |
0.391 |
|
| Show low-probability matches. |